Sionna Therapeutics (NASDAQ:SION) Director Orbimed Advisors Llc Sells 226,906 Shares

Key Points

• Orbimed Advisors sold 226,906 Sionna shares on April 16 at an average of $45.34 for about $10.29M, reducing its stake by 6.99% to 3,020,119 shares; the trade was executed under a pre-arranged Rule 10b5-1 plan and was part of several recent sales totaling roughly $24.3M.
• Sionna shares traded around $45.24 (near a 1-year high of $46.10) with elevated volume, and analysts hold a consensus " Moderate Buy " rating with an average price target of $50.57 following a quarterly EPS beat.

Sionna Therapeutics, Inc. (NASDAQ:SION - Get Free Report) Director Orbimed Advisors Llc sold 226,906 shares of the business's stock in a transaction dated Thursday, April 16th. The shares were sold at an average price of $45.34, for a total transaction of $10,287,918.04. Following the completion of the sale, the director owned 3,020,119 shares in the company, valued at approximately $136,932,195.46. This trade represents a 6.99% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Orbimed Advisors Llc also recently made the following trade(s):

• On Wednesday, April 15th, Orbimed Advisors Llc sold 235,863 shares of Sionna Therapeutics stock. The shares were sold at an average price of $44.64, for a total value of $10,528,924.32.
• On Tuesday, April 14th, Orbimed Advisors Llc sold 47,814 shares of Sionna Therapeutics stock. The shares were sold at an average price of $44.51, for a total value of $2,128,201.14.
• On Tuesday, February 3rd, Orbimed Advisors Llc sold 29,063 shares of Sionna Therapeutics stock. The stock was sold at an average price of $44.58, for a total value of $1,295,628.54.
• On Monday, February 2nd, Orbimed Advisors Llc sold 1,890 shares of Sionna Therapeutics stock. The stock was sold at an average price of $44.57, for a total value of $84,237.30.

Sionna Therapeutics Price Performance

Shares of NASDAQ SION traded up $0.15 during mid-day trading on Thursday, hitting $45.24. 817,609 shares of the company were exchanged, compared to its average volume of 382,339. The stock has a 50 day simple moving average of $37.40 and a 200-day simple moving average of $38.18. Sionna Therapeutics, Inc. has a 1-year low of $9.39 and a 1-year high of $46.10.

Sionna Therapeutics (NASDAQ:SION - Get Free Report) last issued its quarterly earnings results on Monday, March 2nd. The company reported ($0.46) earnings per share for the quarter, topping the consensus estimate of ($0.61) by $0.15.

Wall Street Analyst Weigh In

Several research firms have issued reports on SION. Guggenheim increased their price objective on Sionna Therapeutics from $45.00 to $50.00 and gave the stock a "buy" rating in a research report on Monday, March 2nd. UBS Group reiterated a "buy" rating on shares of Sionna Therapeutics in a research report on Monday, March 2nd. Citizens Jmp began coverage on Sionna Therapeutics in a research report on Tuesday, February 24th. They issued a "market outperform" rating and a $63.00 price objective for the company. Weiss Ratings reiterated a "sell (e+)" rating on shares of Sionna Therapeutics in a research report on Monday, December 29th. Finally, Lifesci Capital upgraded Sionna Therapeutics to a "strong-buy" rating in a research report on Wednesday, February 25th. Two investment analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, Sionna Therapeutics currently has an average rating of "Moderate Buy" and an average price target of $50.57.

Hedge Funds Weigh In On Sionna Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of SION. Invesco Ltd. acquired a new stake in shares of Sionna Therapeutics during the 4th quarter valued at approximately $4,573,000. XTX Topco Ltd acquired a new stake in shares of Sionna Therapeutics during the 4th quarter valued at approximately $203,000. Superstring Capital Management LP acquired a new stake in shares of Sionna Therapeutics during the 4th quarter valued at approximately $7,430,000. Artia Global Partners LP acquired a new stake in shares of Sionna Therapeutics during the 4th quarter valued at approximately $4,926,000. Finally, Balyasny Asset Management L.P. acquired a new stake in shares of Sionna Therapeutics during the 4th quarter valued at approximately $58,000.

About Sionna Therapeutics

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.